Wire · opportunities
Aptitude Announces FDA 510(k) Clearance of Next-Generation Metrix® COVID Test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
Aptitude received FDA 510(k) clearance for its next-generation Metrix COVID Test, enhancing molecular testing accessibility with improved sensitivity and faster results. The company is advancing its molecular diagnostics platform with a transition from emergency use authorizations to traditional FDA clearances and expanding its test menu for decentralized healthcare settings.
This Wire brief sits within Fusion42's coverage of Health, and 5 sources have reported it between 16 Sep 2026 and 18 Sep 2026.
◆ ◆ The Wire takeaway
You can now market molecular covid tests in urgent care with FDA clearance replacing emergency use rules, opening distribution channels and pushing you to update regulatory compliance immediately. The shift means your testing technology must combine speed and sensitivity to compete as devices scale beyond traditional labs.
◆ Coverage
5 sources · first reported 16 Sep 2026 · latest 18 Sep 2026
◆ Related on Wire
◆ Topics